Atara Biotherapeutics Expands T-Cell Immunotherapy Collaboration to Advance Next-Generation CAR T Technologies … – GlobeNewswire (press release)
Week Herald |
Atara Biotherapeutics Expands T-Cell Immunotherapy Collaboration to Advance Next-Generation CAR T Technologies …
GlobeNewswire (press release) Entry into genetically engineered T-cells marks next step in Atara’s strategy to advance leadership position in off-the-shelf, allogeneic T-cell immunotherapy. SOUTH SAN FRANCISCO, Calif., May 08, 2018 (GLOBE NEWSWIRE) — Atara Biotherapeutics, Inc … Atara Biotherapeutics, Inc.StreetInsider.com Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)P&T Community Genentech R&D leader Dietmar Berger moves to Atara Bio, heading up off-the-shelf T cell workEndpoints News |
STAT |
The Amish pool resources for their medical care. A budget-busting gene therapy puts them in a bind
STAT Then again, at $850,000 a person, Luxturna 1 was more budget-busting than just about any other drug. Spark had proposed a few different ways of helping insurers to cover the gene therapy 2 — but Dr. Kevin Strauss’ patients tend not to have insurance … |